Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist

• Published in: Hypertension research Vol. 36; no. 10; pp. 879 - 884
• Main Authors: Sato, Atsuhisa, Fukuda, Seiichi
• Format: Journal Article
• Language: English
• Published: England 01-10-2013
• Subjects: Aged; Albuminuria - epidemiology; Albuminuria - etiology; Albuminuria - metabolism; Aldosterone - metabolism; Amides - pharmacology; Amides - therapeutic use; Blood Pressure - drug effects; Blood Pressure - physiology; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fumarates - pharmacology; Fumarates - therapeutic use; Humans; Hypertension - complications; Hypertension - drug therapy; Hypertension - metabolism; Incidence; Longitudinal Studies; Male; Middle Aged; Mineralocorticoid Receptor Antagonists - pharmacology; Mineralocorticoid Receptor Antagonists - therapeutic use; Renin - antagonists & inhibitors; Renin - metabolism; Renin-Angiotensin System - drug effects; Renin-Angiotensin System - physiology; Spironolactone - analogs & derivatives; Spironolactone - pharmacology; Spironolactone - therapeutic use; Time Factors
• ISSN: 0916-9636; 1348-4214
• DOI: 10.1038/hr.2013.74

We have reported observing aldosterone breakthrough in the course of relatively long-term treatment with renin-angiotensin (RA) system inhibitors, where the plasma aldosterone concentration (PAC) increased following an initial decrease. Aldosterone breakthrough has the potential to eliminate the organ-protective effects of RA system inhibitors. We therefore conducted a study in essential hypertensive patients to determine whether aldosterone breakthrough occurred during treatment with the direct renin inhibitor (DRI) aliskiren and to ascertain its clinical significance. The study included 40 essential hypertensive patients (18 men and 22 women) who had been treated for 12 months with aliskiren. Aliskiren significantly decreased blood pressure and plasma renin activity (PRA). The PAC was also decreased significantly at 3 and 6 months; however, the significant difference disappeared after 12 months. Aldosterone breakthrough was observed in 22 of the subjects (55%). Urinary albumin excretion differed depending on whether breakthrough occurred. For the subjects in whom aldosterone breakthrough was observed, eplerenone was added. A significant decrease in urinary albumin excretion was observed after 1 month, independent of changes in blood pressure. In conclusion, this study demonstrated that aldosterone breakthrough occurs in some patients undergoing DRI therapy. Aldosterone breakthrough affects the drug's ability to improve urinary albumin excretion, and combining a mineralocorticoid receptor antagonist with the DRI may be useful for decreasing urinary albumin excretion. When the objective is organ protection in hypertensive patients, a two-pronged approach using combination therapy to inhibit both the RA system and aldosterone may be highly effective.